MEDIGOO expands in Europe – Planning IPO preparations in 2020
Dr. Mika Karilahti, CEO, has a long experience in Director roles at Nokia Sourcing and Samsung Sales, and additionally he has managed a Webhosting company and later sold that business to Nebula. Earlier he managed an accounting office and later sold its business to another accounting & auditing company. His skills are in the areas of Technology, Sourcing, Sales, and Financial accounting.
Mr. Teemu Polo, Chairman of the Board, has worked with and within startups since ~2004 and currently works at New Company Consulting unit (NewCo) run by the City of Helsinki in Finland. He is at his best with business development.
Ms. Pia Ali-Tolppa, Member of the Board, works as CEO at Bonum Bank Oy. She is bringing her competences in the Finance sector, IT, HR, Management accounting, Risk Control and Digitalisation. Her earlier employment has been VP at SEB, and CFO at Wello.
Ms. Riikka Friman, Member of the Board, works as Vice President, Digital and Content Marketing at F-Secure Oyj. Her experience is in brand management, sales development in digital and distribution channels. Her previous positions have been in brand management at Rautaruukki and Kemira.
Mr. Jussi Kivikari, Member of the Board, works as Development Director at The Finnish Fair Corporation. He brings experience in event marketing and B2B sales.
14 March 2019 – 31 June 2020
2 480,43 € (2787 pcs shares) Crowdfunding platform will incur some additional costs to the share subscriber.
No minimum, the issuance of the shares shall commence without any cancellations, all subscriptions above minimum subscription will be executed.
2 000 000 € (2 229 927 pcs shares )
Medigoo Oy Inc.
Company shares are being moved into the Finland Euroclear maintained ownership register, but they are not yet being traded on any regulated marketplace or multi-marketplace. There is currently no working aftermarket. In the Euroclear system the shareholder is required to open a holding account with a local bank or trader in Finland. Foreign investors shall be using the nominee register system.
Medigoo Oy Inc.
Investor can obtain yield with the increase of the share valuation, aiming towards First North stock listing in 2020.
High risk investment to growth company common stock carrying voting rights.
25 % (with the assumption of fully subscribed share emission).
In the Company’s view, the company valuation before the issuance of the shares is EUR 6,000,000. The Company valuation after the issuance of the shares is EUR 8,000,000 if the issuance is fully exercised. The valuation has been calculated by indicating the total amount of the Company shares, stock options and other rights entitling to shares at the commencement of the Offering at the subscription price used in connection with the Offering.
Medigoo Oy has only one class of shares in use. All the shares on the date of the marketing attachment belong to the same class of common stock.